Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:34:57 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:VRTX - VERTEX PHARMACEUTICAL - http://www.vpharm.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRTX - Q1.4393.01·393.141.6393.28-0.20-0.1617.3242,33212,241394.545  396.98  392.995448.40  316.4314:18:01Apr 1815 min RT 2¢

Recent Trades - Last 10 of 12241
Time ETExPriceChangeVolume
14:18:05Q393.115-0.3656
14:18:01Q393.0953-0.38471
14:18:01Q393.12-0.361
14:18:01Q393.13-0.352
14:17:59Q393.03-0.4572
14:17:51Q393.01-0.476
14:17:49Q393.146-0.3341
14:17:20Q393.18-0.301
14:17:17Q393.0001-0.47994
14:17:17Q393.2033-0.27671

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 08:00U:VRTXNews ReleaseVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
2024-04-10 16:01U:VRTXNews ReleaseVertex Enters Into Agreement to Acquire Alpine Immune Sciences
2024-04-09 16:05U:VRTXNews ReleaseVertex to Announce First Quarter 2024 Financial Results on May 6
2024-04-01 11:00U:VRTXNews ReleaseVertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-04-01 08:00U:VRTXNews ReleaseVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
2024-03-21 08:00U:VRTXNews ReleaseVertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2024-02-20 16:05U:VRTXNews ReleaseVertex to Participate in Upcoming Investor Conferences
2024-02-13 01:59U:VRTXNews ReleaseEuropean Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2024-02-05 16:06U:VRTXNews ReleaseVertex Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-05 16:01U:VRTXNews ReleaseVertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
2024-01-30 06:28U:VRTXNews ReleaseVertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
2024-01-17 08:00U:VRTXNews ReleaseVertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
2024-01-16 14:24U:VRTXNews ReleaseVertex Announces US FDA Approval of CASGEVY ¢ „ ¢ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
2024-01-09 12:42U:VRTXNews ReleaseVertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
2024-01-07 15:00U:VRTXNews ReleaseVertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
2023-12-18 16:05U:VRTXNews ReleaseVertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
2023-12-15 08:12U:VRTXNews ReleaseVertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY ¢ „ ¢ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-12-13 06:30U:VRTXNews ReleaseVertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy